Skip to main content
Top
Published in: Annals of Surgical Oncology 2/2015

01-02-2015 | Endocrine Tumors

Level 7 Disease Does Not Confer Worse Outcome than Level 6 Disease in Differentiated Thyroid Cancer

Authors: Laura Y. Wang, MBBS, MS, Frank L. Palmer, BA, Dorothy Thomas, BA, Iain J. Nixon, MBChB, R. Michael Tuttle, MD, Jatin P. Shah, MD, Snehal G. Patel, MD, Ashok R. Shaha, MD, Ian Ganly, MD, PhD

Published in: Annals of Surgical Oncology | Issue 2/2015

Login to get access

Abstract

Background

Level 7 nodal disease increases patients from N1a to N1b in the American Joint Committee on Cancer (AJCC) TNM classification of differentiated thyroid cancers (DTCs). This results in upstaging of patients older than 45 years of age from stage III to IV. Our objective was to determine if patients with level 7 disease had poorer outcome in comparison to patients with isolated level 6 disease.

Methods

A total of 599 patients with DTC limited to the central neck (level 6 and 7) were identified from an institutional database. Patients with N1b disease due to lateral compartment (level 1–5) involvement or M1 disease were excluded. Fifty-seven patients had positive level 7 disease, and 542 patients had nodal disease limited to level 6. Disease-specific survival (DSS) and recurrence-free survival (RFS) were calculated for each group.

Results

Median age was 41 years (range 12–91) and follow-up was 61 months (range 1–330). There were no disease-specific deaths at 5 years. Among patients with level 6 disease at presentation, there were 42 nodal recurrences, and among patients with level 7 disease, there were two recurrences. There were no differences in overall RFS between patients with level 6 or 7 disease (5-year RFS 90.7 vs. 98.2 %, respectively; p = 0.096).

Conclusions

Our results suggest that N1b disease due to level 7 disease does not confer worse DSS or RFS compared with patients with level 6 disease only. Classifying all central neck disease (levels 6 and 7) into the N1a category, and reserving the N1b classification only for patients with lateral neck disease may be more reflective of prognosis.
Literature
1.
go back to reference Sobin L, Gospodarowicz M, Wittekind C. International Union Against Cancer (UICC) TNM classification of malignant tumors. 7th ed. New York: Wiley-Blackwell; 2009. New York: Springer Sobin L, Gospodarowicz M, Wittekind C. International Union Against Cancer (UICC) TNM classification of malignant tumors. 7th ed. New York: Wiley-Blackwell; 2009. New York: Springer
2.
go back to reference Ito Y, Tomoda C, Uruno T, Takamura Y, Miya A, Kobayashi K, et al. Ultrasonographically and anatomopathologically detectable node metastases in the lateral compartment as indicators of worse relapse-free survival in patients with papillary thyroid carcinoma. World J Surg. 2005;29:917-920PubMedCrossRef Ito Y, Tomoda C, Uruno T, Takamura Y, Miya A, Kobayashi K, et al. Ultrasonographically and anatomopathologically detectable node metastases in the lateral compartment as indicators of worse relapse-free survival in patients with papillary thyroid carcinoma. World J Surg. 2005;29:917-920PubMedCrossRef
3.
go back to reference de Meer SG, Dauwan M, de Keizer B, Valk GD, Borel Rinkes IH, Vriens MR. Not the number but the location of lymph nodes matters for recurrence rate and disease-free survival in patients with differentiated thyroid cancer. World J Surg. 2012;36:1262-1267PubMedCentralPubMedCrossRef de Meer SG, Dauwan M, de Keizer B, Valk GD, Borel Rinkes IH, Vriens MR. Not the number but the location of lymph nodes matters for recurrence rate and disease-free survival in patients with differentiated thyroid cancer. World J Surg. 2012;36:1262-1267PubMedCentralPubMedCrossRef
4.
go back to reference Ito Y, Miyauchi A. Lateral lymph node dissection guided by preoperative and intraoperative findings in differentiated thyroid carcinoma. World J Surg. 2008;32:729-739.PubMedCrossRef Ito Y, Miyauchi A. Lateral lymph node dissection guided by preoperative and intraoperative findings in differentiated thyroid carcinoma. World J Surg. 2008;32:729-739.PubMedCrossRef
5.
go back to reference Ito Y, Miyauchi A, Jikuzono T, Higashiyama T, Takamura Y, Miya A, et al. Risk factors contributing to a poor prognosis of papillary thyroid carcinoma: validity of UICC/AJCC TNM classification and stage grouping. World J Surg. 2007;31:838-848.PubMedCrossRef Ito Y, Miyauchi A, Jikuzono T, Higashiyama T, Takamura Y, Miya A, et al. Risk factors contributing to a poor prognosis of papillary thyroid carcinoma: validity of UICC/AJCC TNM classification and stage grouping. World J Surg. 2007;31:838-848.PubMedCrossRef
6.
go back to reference DeGroot LJ, Kaplan EL, McCormick M, Straus FH. Natural history, treatment, and course of papillary thyroid carcinoma. J Clin Endocrinol Metab. 1990;71:414-424PubMedCrossRef DeGroot LJ, Kaplan EL, McCormick M, Straus FH. Natural history, treatment, and course of papillary thyroid carcinoma. J Clin Endocrinol Metab. 1990;71:414-424PubMedCrossRef
7.
go back to reference Hay ID, Bergstralh EJ, Goellner JR, Ebersold JR, Grant CS. Predicting outcome in papillary thyroid carcinoma: development of a reliable prognostic scoring system in a cohort of 1779 patients surgically treated at one institution during 1940 through 1989. Surgery. 1993;114:1050-1057; discussion 1057-1058PubMed Hay ID, Bergstralh EJ, Goellner JR, Ebersold JR, Grant CS. Predicting outcome in papillary thyroid carcinoma: development of a reliable prognostic scoring system in a cohort of 1779 patients surgically treated at one institution during 1940 through 1989. Surgery. 1993;114:1050-1057; discussion 1057-1058PubMed
8.
go back to reference Grebe SK, Hay ID. Thyroid cancer nodal metastases: biologic significance and therapeutic considerations. Surg Oncol Clin N Am. 1996;5:43-63PubMed Grebe SK, Hay ID. Thyroid cancer nodal metastases: biologic significance and therapeutic considerations. Surg Oncol Clin N Am. 1996;5:43-63PubMed
9.
go back to reference Sobin L, Wittekind C. UICC: TNM classification of malignant tumors. 5th ed. New York: Wiley, 1997. Sobin L, Wittekind C. UICC: TNM classification of malignant tumors. 5th ed. New York: Wiley, 1997.
10.
go back to reference Sobin L, Wittekind C. International Union Against Cancer (UICC) TNM classification of malignant tumors. 6th ed. New York: Wiley-Liss; 2002:78 Sobin L, Wittekind C. International Union Against Cancer (UICC) TNM classification of malignant tumors. 6th ed. New York: Wiley-Liss; 2002:78
11.
go back to reference Gimm O, Rath FW, Dralle H. Pattern of lymph node metastases in papillary thyroid carcinoma. Br J Surg. 1998;85:252-254PubMedCrossRef Gimm O, Rath FW, Dralle H. Pattern of lymph node metastases in papillary thyroid carcinoma. Br J Surg. 1998;85:252-254PubMedCrossRef
12.
go back to reference Scheumann GF, Gimm O, Wegener G, Hundeshagen H, Dralle H. Prognostic significance and surgical management of locoregional lymph node metastases in papillary thyroid cancer. World J Surg. 1994;18:559-567; discussion 567-558PubMedCrossRef Scheumann GF, Gimm O, Wegener G, Hundeshagen H, Dralle H. Prognostic significance and surgical management of locoregional lymph node metastases in papillary thyroid cancer. World J Surg. 1994;18:559-567; discussion 567-558PubMedCrossRef
13.
go back to reference Ito Y, Jikuzono T, Higashiyama T, Asahi S, Tomoda C, Takamura Y, et al. Clinical significance of lymph node metastasis of thyroid papillary carcinoma located in one lobe. World J Surg. 2006;30:1821-1828PubMedCrossRef Ito Y, Jikuzono T, Higashiyama T, Asahi S, Tomoda C, Takamura Y, et al. Clinical significance of lymph node metastasis of thyroid papillary carcinoma located in one lobe. World J Surg. 2006;30:1821-1828PubMedCrossRef
14.
go back to reference Randolph G, Duh Q, Heller K, LiVolsi V, Mandel S, Steward D, et al. The prognostic significance of nodal metastases from papillary thyroid carcinoma can be stratified based on the size and number of metastatic lymph nodes, as well as the presence of extranodal extension. Thyroid. 2012;22:1144-1152.PubMedCrossRef Randolph G, Duh Q, Heller K, LiVolsi V, Mandel S, Steward D, et al. The prognostic significance of nodal metastases from papillary thyroid carcinoma can be stratified based on the size and number of metastatic lymph nodes, as well as the presence of extranodal extension. Thyroid. 2012;22:1144-1152.PubMedCrossRef
15.
go back to reference Sugitani I, Kasai N, Fujimoto Y, Yanagisawa A. A novel classification system for patients with PTC: addition of the new variables of large (3 cm or greater) nodal metastases and reclassification during the follow-up period. Surgery. 2004;135:139-148PubMedCrossRef Sugitani I, Kasai N, Fujimoto Y, Yanagisawa A. A novel classification system for patients with PTC: addition of the new variables of large (3 cm or greater) nodal metastases and reclassification during the follow-up period. Surgery. 2004;135:139-148PubMedCrossRef
16.
go back to reference Takada H, Kikumori T, Imai T, Sawaki M, Shibata A, Kiuchi T. Patterns of lymph node metastases in papillary thyroid carcinoma: results from consecutive bilateral cervical lymph node dissection. World J Surg. 2011;35:1560-1566PubMedCrossRef Takada H, Kikumori T, Imai T, Sawaki M, Shibata A, Kiuchi T. Patterns of lymph node metastases in papillary thyroid carcinoma: results from consecutive bilateral cervical lymph node dissection. World J Surg. 2011;35:1560-1566PubMedCrossRef
17.
go back to reference Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, Mandel SJ, et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2009;19:1167-1214PubMedCrossRef Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, Mandel SJ, et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2009;19:1167-1214PubMedCrossRef
19.
go back to reference Pacini F, Schlumberger M, Dralle H, Elisei R, Smit JW, Wiersinga W. European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. Eur J Endocrinol. 2006;154:787-803PubMedCrossRef Pacini F, Schlumberger M, Dralle H, Elisei R, Smit JW, Wiersinga W. European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. Eur J Endocrinol. 2006;154:787-803PubMedCrossRef
20.
go back to reference Takami H, Ito Y, Okamoto T, Yoshida A. Therapeutic strategy for differentiated thyroid carcinoma in Japan based on a newly established guideline managed by Japanese Society of Thyroid Surgeons and Japanese Association of Endocrine Surgeons. World J Surg. 2011;35:111-121PubMedCrossRef Takami H, Ito Y, Okamoto T, Yoshida A. Therapeutic strategy for differentiated thyroid carcinoma in Japan based on a newly established guideline managed by Japanese Society of Thyroid Surgeons and Japanese Association of Endocrine Surgeons. World J Surg. 2011;35:111-121PubMedCrossRef
Metadata
Title
Level 7 Disease Does Not Confer Worse Outcome than Level 6 Disease in Differentiated Thyroid Cancer
Authors
Laura Y. Wang, MBBS, MS
Frank L. Palmer, BA
Dorothy Thomas, BA
Iain J. Nixon, MBChB
R. Michael Tuttle, MD
Jatin P. Shah, MD
Snehal G. Patel, MD
Ashok R. Shaha, MD
Ian Ganly, MD, PhD
Publication date
01-02-2015
Publisher
Springer US
Published in
Annals of Surgical Oncology / Issue 2/2015
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-014-4045-3

Other articles of this Issue 2/2015

Annals of Surgical Oncology 2/2015 Go to the issue